BioNTech (NASDAQ:BNTX) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen lowered shares of BioNTech (NASDAQ:BNTX) from a hold rating to a sell rating in a research report released on Saturday.

Other equities research analysts have also recently issued reports about the company. Morgan Stanley decreased their price target on BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research note on Wednesday, July 8th. Berenberg Bank cut their price objective on shares of BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. Citigroup decreased their price objective on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research report on Wednesday. UBS Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $117.00 to $135.00 in a research note on Wednesday, May 27th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $127.81.

BioNTech Price Performance

BNTX opened at $93.67 on Friday. The firm has a market capitalization of $23.69 billion, a PE ratio of -11.96 and a beta of 1.27. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 8.74. The business’s 50-day moving average is $91.36 and its two-hundred day moving average is $96.93. BioNTech has a 1 year low of $79.52 and a 1 year high of $124.00.

BioNTech announced that its board has initiated a stock repurchase program on Thursday, May 7th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 4.2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On BioNTech

Institutional investors have recently added to or reduced their stakes in the stock. Larson Financial Group LLC boosted its stake in BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. EFG International AG acquired a new stake in shares of BioNTech in the fourth quarter valued at about $29,000. Caitong International Asset Management Co. Ltd raised its position in shares of BioNTech by 520.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after buying an additional 260 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after buying an additional 305 shares in the last quarter. Finally, Vestcor Inc acquired a new position in BioNTech during the fourth quarter worth about $153,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.